MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-490-2965
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees68
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions
What is MeiraGTx's stock symbol?
MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."
How were MeiraGTx's earnings last quarter?
MeiraGTx Holdings PLC (NASDAQ:MGTX) released its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.63) EPS for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.47. The business had revenue of $1.98 million for the quarter. View MeiraGTx's Earnings History.
When is MeiraGTx's next earnings date?
What price target have analysts set for MGTX?
3 equities research analysts have issued 12-month target prices for MeiraGTx's shares. Their forecasts range from $30.00 to $40.00. On average, they anticipate MeiraGTx's stock price to reach $36.6667 in the next year. This suggests a possible upside of 91.3% from the stock's current price. View Analyst Price Targets for MeiraGTx.
What is the consensus analysts' recommendation for MeiraGTx?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.
What are Wall Street analysts saying about MeiraGTx stock?
Here are some recent quotes from research analysts about MeiraGTx stock:
- 1. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (5/29/2019)
- 2. Chardan Capital analysts commented, "We reiterate that the Johnson & Johnson (unrated) deals (collaboration 1, 2; equity stake) signal positive upcoming datasets for MeiraGTx in 2019, particularly in XLRP and achromatopsia, since J&J had seen all in-house data prior to the announced 2019 deals. (See our 31 January 2019 and 27 February 2019 research.) To us, today’s announced AAV-RPE65 data are a positive step for Meira towards building a formidable portfolio of GTs for inherited retinal diseases (IRDs). Though questions still remain on how AAV-RPE65 will make progress once on the market given that Luxturna has already seen regulatory approval, the phase I/II data increase the prospects for AAV-RPE65. As noted in our initiation, we model $0.0 in risk-adjusted sales for AAV-RPE65, which to us is now inconsistent with today’s data communication. We shall update our forecasts with a future model update." (5/14/2019)
Has MeiraGTx been receiving favorable news coverage?
Press coverage about MGTX stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. MeiraGTx earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for MeiraGTx.
Are investors shorting MeiraGTx?
MeiraGTx saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 458,200 shares, a decrease of 47.6% from the July 31st total of 874,600 shares. Based on an average daily trading volume, of 181,200 shares, the days-to-cover ratio is currently 2.5 days. Currently, 2.3% of the company's shares are short sold. View MeiraGTx's Current Options Chain.
Who are some of MeiraGTx's key competitors?
Some companies that are related to MeiraGTx include Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Regenxbio (RGNX), Coherus Biosciences (CHRS), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI) and Twist Bioscience (TWST).
What other stocks do shareholders of MeiraGTx own?
Who are MeiraGTx's key executives?
MeiraGTx's management team includes the folowing people:
- Dr. Alexandria Forbes, CEO, Pres & Director (Age 54)
- Mr. Richard Brian Giroux, Chief Operating Officer (Age 46)
- Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 56)
- Ms. Katherine Edna Breedis C.F.A., CFA, CMT, Chief Financial Officer
- Mr. Micah Zajic, VP of Corp. Devel.
When did MeiraGTx IPO?
(MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.
Who are MeiraGTx's major shareholders?
MeiraGTx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (7.75%), BlackRock Inc. (2.37%), JPMorgan Chase & Co. (0.51%), AE Wealth Management LLC (0.40%), Northern Trust Corp (0.36%) and Vanguard Group Inc. (0.30%). View Institutional Ownership Trends for MeiraGTx.
Which major investors are selling MeiraGTx stock?
Which major investors are buying MeiraGTx stock?
MGTX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Orbimed Advisors LLC, Nuveen Asset Management LLC, Vanguard Group Inc., Panagora Asset Management Inc., Renaissance Technologies LLC and Swiss National Bank. View Insider Buying and Selling for MeiraGTx.
How do I buy shares of MeiraGTx?
Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is MeiraGTx's stock price today?
One share of MGTX stock can currently be purchased for approximately $19.17.
How big of a company is MeiraGTx?
MeiraGTx has a market capitalization of $639.68 million. The company earns $-82,870,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.View Additional Information About MeiraGTx.
What is MeiraGTx's official website?
How can I contact MeiraGTx?
MeiraGTx's mailing address is 430 EAST 29TH STREET 10TH FLOOR, NEW YORK NY, 10016. The company can be reached via phone at 646-490-2965 or via email at [email protected]
MarketBeat Community Rating for MeiraGTx (NASDAQ MGTX)
MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote "Outperform" if you believe MGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
